MESENCHYMAL STEM CELLS AND USES THEREFOR

• US 20090220464A1
• Filed: 03/21/2008
• Published: 09/03/2009
• Est. Priority Date: 03/22/2004
• Status: Abandoned Application

• Current Assignee: Mesoblast International Srl
• Original Assignee: Mesoblast International Srl
• Inventors: Varney, Timothy, Aggarwal, Sudeepta, Pittenger, Mark F., Danilkovitch, Alla
• Application Number:
  US12/091,370
• Publication Number:
  US 20090220464A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 2035/122 for inducing tolerance or supression of immune responses
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Claims

1. A method of promoting angiogenesis in an organ or tissue of an animal other than the heart, comprising:

administering to said animal mesenchymal stem cells in an amount effective to promote angiogenesis in an organ or tissue other than the heart of said animal.

2. The method of claim 1 wherein said animal is a mammal.

3. The method of claim 2 wherein said mammal is a primate.

4. The method of claim 3 wherein said primate is a human.

5. The method of claim 1 wherein said mesenchymal stem cells are administered in an amount of from about 1×

10⁵ cells/kg to about 1×

10⁷ cells/kg.

6. The method of claim 5 wherein said mesenchymal stem cells are administered in an amount of from about 1×

10⁶ cells/kg to about 5×

10⁶ cells/kg.

7. The method of claim 1 wherein said mesenchymal stem cells are administered systemically.

8. The method of claim 1 wherein said mesenchymal stem cells are administered intravenously.

9. The method of claim 1 wherein said mesenchymal stem cells are administered by direct injection to said organ or tissue other than the heart of said animal.

10. A method of treating a disease selected from the group consisting of autoimmune diseases and graft-versus-host in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said disease in said animal

11. The method of claim 10 wherein said animal is a mammal

12. The method of claim 11 wherein said mammal is a human.

13. The method of claim 10 wherein said disease is multiple sclerosis.

14. A method of treating an inflammatory response in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said inflammatory response in said animal.

15. The method of claim 14 wherein said animal is a mammal.

16. The method of claim 15 wherein said mammal is a human.

17. The method of claim 14 wherein said inflammatory response is associated with psoriasis.

24. The method of claim 14 wherein said allergic disease or disorder is arthritis.

18. A method of treating cancer in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat cancer in said animal.

19. The method of claim 18 wherein said animal is a mammal.

20. The method of claim 19 wherein said mammal is a human.

21. A method of treating an allergic disease or disorder in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat said allergic disease or disorder in said animal.

22. The method of claim 21 wherein said animal is a mammal.

23. The method of claim 22 wherein said mammal is a human.

25. A method of promoting wound healing in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to promote wound healing in said animal.

26. The method of claim 25 wherein said animal is a mammal.

27. The method of claim 26 wherein said mammal is a human.

28. A method of treating or preventing a fibrotic disorder in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to treat or prevent said fibrotic disorder in said animal.

29. The method of claim 28 wherein said fibrotic disorder is Acute Respiratory Distress Syndrome.

30. The method of claim 28 wherein said fibrotic disorder is Chronic Obstructive Pulmonary Disease.

31. The method of claim 28 wherein said fibrotic disorder is Idiopathic Pulmonary Fibrosis.

32. A method of repairing epithelial damage in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to repair epithelial damage in said animal.

33. The method of claim 32 wherein said animal is a mammal.

34. The method of claim 33 wherein said mammal is a human.

35. The method of claim 32 wherein said epithelial damage is a result of graft-versus-host disease.

36. A method of treating a pulmonary disease in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to repair a pulmonary disease in said animal.

37. The method of claim 36 wherein said pulmonary disease has fibrotic and inflammatory components.

38. The method of claim 36 wherein said pulmonary disease is Chronic Obstructive Pulmonary Disease.

39. A method of improving pulmonary function in an animal, comprising:

administering to said animal mesenchymal stem cells in an amount effective to improve pulmonary function in said animal.

40. The method of claim 39 wherein said mesenchymal stem cells are administered in an amount from about 0.5×

10⁶ cells per kilogram of body weight to about 5.0×

10⁶ cells per kilogram of body weight.

41. The method of claim 39 wherein said mesenchymal stem cells are administered in an amount effective to improve forced expiratory volume in said patient.

42. The method of claim 41 wherein said mesenchymal stem cells are administered in an amount effective to improve forced expiratory volume by at least 10% in said patient.